Cipla inches up on the BSE
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Cipla is currently trading at Rs. 1122.60, up by 0.10 points or 0.01% from its previous closing of Rs. 1122.50 on the BSE.
The scrip opened at Rs. 1122.00 and has touched a high and low of Rs. 1147.35 and Rs. 1117.50 respectively. So far 151608 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1185.20 on 01-Nov-2022 and a 52 week low of Rs. 860.10 on 21-Jan-2022.
Last one week high and low of the scrip stood at Rs. 1147.45 and Rs. 1085.10 respectively. The current market cap of the company is Rs. 90375.37 crore.
The promoters holding in the company stood at 33.61%, while Institutions and Non-Institutions held 49.37% and 17.01% respectively.
Cipla has launched Leuprolide Acetate Injection Depot 22.5mg. The product was approved by the United States Food and Drug Administration (US FDA) based on a New Drug Application (NDA) submitted under the 505(b)(2) regulatory pathway. Leuprolide Acetate Injection Depot contains 22.5 mg of leuprolide acetate for 3- month administration given as a single dose injection.
It is supplied as lyophilized microspheres in a single dose vial as a kit with a prefilled syringe containing 2mL 0.8% mannitol solution and an easy-to-use MIXJECT transfer device for a single dose injection. It is indicated for palliative treatment of advanced prostate cancer. The active ingredient, route of administration, dosage form and strength are the same as LUPRON DEPOT 22.5 mg strength, from Abbvie. According to IQVIA, LUPRON DEPOT 22.5mg had US sales of approximately $197M for the 12-month period ending September 2022.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
